Auto-generated from public data. Not the firm's stated position.
Based on disclosed data, Debiopharm Innovation Fund appears to focus on early-stage healthtech companies that leverage AI and data technologies to address clinical and operational challenges, with particular emphasis on privacy-preserving solutions and oncology applications across pre-seed through Series B stages.
Generated 16 Aug 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
€3M – €5M
Website reachable as of Oct 2026. Focus and check size as listed by the firm, not independently verified.
Learn what Debiopharm Innovation Fund and similar investors look for:
Healthtech pitch guideTips, programs, and cultural notes
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.